Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21719818 | 1.00 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22487883 | 1.00 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11015815 | 1.00 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19186683 | 0.98 | CYP19A1 (0.36) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21191816 | 0.97 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25627105 | 0.90 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17803621 | 0.89 | CYP1A2 (0.31) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22059382 | 0.86 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27922362 | 0.84 | CYP19A1 (0.38) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11306595 | 0.82 | CYP19A1 (0.39) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230067355-A1 | 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-one Derivatives Useful As Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-02 | — | — | US | disclosed |
| US-11071731-B2 | Allosteric modulators of the mu opioid receptor | Chiromics, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200276177-A1 | Allosteric Modulators of the Mu Opioid Receptor | Chiromics, LLC (US) | 2020-09-03 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CYP19A1 670/4885CYP1A2 311/4885CYP3A4 418/4885 |
| US-20230067355-A1 | 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-one Derivatives Useful As Factor XIa Inhibitors | SERPINE1, SERPINC1, F11 | CYP19A1 371/4885CYP1A2 840/4885CYP3A4 1399/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | CYP19A1 670/4885CYP1A2 311/4885CYP3A4 418/4885 |
| US-20200276177-A1 | Allosteric Modulators of the Mu Opioid Receptor | OPRM1, OPRK1, OPRD1 | CYP19A1 2873/4885CYP1A2 994/4885CYP3A4 1603/4885 |
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | KLKB1, F2, SERPINC1 | CYP19A1 227/4885CYP1A2 385/4885CYP3A4 436/4885 |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | CYP19A1 3173/4885CYP1A2 4679/4885CYP3A4 4707/4885 |
| US-11071731-B2 | Allosteric modulators of the mu opioid receptor | OPRM1, OPRK1, OPRD1 | CYP19A1 2873/4885CYP1A2 994/4885CYP3A4 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.